Clinical efficacy, side effects and patient satisfaction of weekly subcutaneous methotrexate in the treatment of psoriasis in Udonthani Hospital
Keywords:
psoriasis, subcutaneous methotrexate, efficacyAbstract
Oral methotrexate in the treatment of psoriasis may cause gastrointestinal side effects or inadequate response in some patients. There are many studies in rheumatoid arthritis and juvenile rheumatoid arthritis that subcutaneous methotrexate administration could be more effective and less gastrointestinal side effects than oral administration. But in psoriasis, there is no study before.
This is a prospective study in 13 psoriasis patients that had had gastrointestinal side effects or inadequate response after weekly oral methotrexate treatment. The treatment was changed from oral form to subcutaneous injection at the same dose. The clinical efficacy was assessed in 1-4 months. The results showed that 3 patients (23%) had achieved PASI-25, 4 patients (31%) had achieved PASI-50 and 3 patients (23%) had achieved PASI-75. The gastrointestinal side effects assessment showed that 11 patients (85%) had no symptom and 2 patients (15%) had mild nausea. On satisfaction scale of 1-5, the average rating was 3.84, indicated that patients were rather very satisfied with the treatment of subcutaneous methotrexate.
From this study it may be concluded that subcutaneous methotrexate could be more effective and less gastrointestinal side effects than oral methotrexate in the treatment of psoriasis.
References
Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-37.
Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005; 53: 652-9.
Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86-90.
Osman A, Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis 2001; 60: 432.
Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-210.
Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-8.
Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-4.
Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9.
Rozin A, Schapira D, Balbir-Gurman A, et al. Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002; 61: 756-7.
Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
Hameed B, Jones H. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Int J Rheum Dis 2010; 13:e83-4.
Islam MS, Haq SA, Islam MN, Azad AK, Islam MA, Barua R, et al. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J 2013; 22: 483-8.
Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31: 179-82.
Tuková J, Chládek J, Nemcová D, Chládková J, Dolezalová P. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2009; 27: 1047-53.
Trissel LA. Methotrexate sodium AHFS 10:00. In : Trissel LA. Handbook on injectable drugs vol.2. American Society of Health-System Pharmacists, Inc. 2005: 1026-7
Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheumatol 2006; 35: 102-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Thai Journal of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น
